Shilpa Medicare Approves Q1 Results, Announces Strategic Investment of Up To EUR 7 Million in Gate2Brain

Shilpa Medicare Approves Q1 Results, Announces Strategic Investment of Up To EUR 7 Million in Gate2Brain​

Shilpa Medicare Limited announced the approval of its Un-Audited Financial Results (Standalone and Consolidated) for the quarter ending June 30, 2026. The Board meeting held on August 5, 2026, also approved several key corporate actions, including a significant strategic investment into Gate2Brain (G2B).

The Company's subsidiary, Shilpa Biocare Private Limited ("Biocare"), is planning an investment in Gate2Brain, which totals up to EUR 7 million. This proposed investment is intended to be executed in a fungible manner through a combination of cash infusion, equity for services, or development costs associated with the projects.

Financial Performance Highlights​

The Un-Audited Standalone Financial Results showed Total Income at 19,860 lakhs for the quarter ending June 30, 2026. Expenses totaled 15,105 lakhs, resulting in a Net profit of 6,492 lakhs for the period.

The Un-Audited Consolidated Financial Results saw Total Income stand at 46,891 lakhs for the quarter ending June 30, 2026. Total Expenses were reported at 37,682 lakhs, with a resulting Profit after taxes attributable to owners of the Parent Company at 10,088 lakhs.

A summary of the key financial figures (in lakhs) is presented below:

Table 1: Un-Audited Financial Results Summary (Quarter ending June 30, 2026)

Governance and Strategic Appointments​

The Board meeting also approved the appointment of Mr. Sharath Reddy Kalakota (DIN: 03603460), who will serve as a Whole-time Director. He is liable to retire by rotation, subject to members' approval at the upcoming Annual General Meeting (AGM). Mr. Reddy is a postgraduate in Pharmacy and has over three decades of experience in API manufacturing, Operations & Execution of Greenfield and brown field projects.

Furthermore, the Board approved the payment of remuneration to Mr. Madhav Vishnukant Bhutada (DIN: 08222055), Non-Executive Director of Shilpa Biologicals Ltd (SBPL), set at up to 1% net profits of SBPL, effective from April 1, 2026.

AGM and Dividend Details​

The 39th Annual General Meeting (AGM) of Shilpa Medicare Limited is scheduled for Friday, September 11, 2026, commencing at 11:00 AM via video conferencing (VC) or other audio-visual means (OAVM).

The record date for determining the shareholders entitled to receive the final dividend for FY 2025-26 is set as Friday, September 4, 2026. The company has also engaged M/s KFin Technologies Limited to provide remote e-voting facility for the AGM.

Key Dates and Events​

A timeline of important corporate events for shareholders is provided below:

Table 2: Corporate Event Calendar

Divisional and Associate Operations​

The Operating segment of the company is defined as "Pharmaceuticals." The consolidated results reflect a portfolio that includes various subsidiaries and associates. Among the subsidiary listed are Shilpa Pharma Lifesciences Limited, Shilpa Biologicals Private Limited, and Shilpa Biocare Private Limited. Associates include Sravathi Advance Process Technologies Private Limited (SAPL).

The company also noted that the National Company Law Tribunal at Bengaluru Bench sanctioned a Scheme of Merger by Absorption for Shilpa Therapeutics Private Limited with the Company on April 1, 2025.

SHILPAMED Stock Price Movement​

Shares of Shilpa Medicare Limited surged today, climbing over 9.04% in the market to settle at ₹702.9 as investors responded positively to company news. The performance drove the stock near its annual high, with trading volume recording approximately 4.55 million shares during the session.